Psychedelics, OCD and related disorders: A systematic review

IF 1.9 4区医学 Q3 PSYCHIATRY

Journal of Obsessive-Compulsive and Related Disorders Pub Date : 2024-04-01 DOI:10.1016/j.jocrd.2024.100873

Marianna Graziosi , Julia S. Rohde , Praachi Tiwari , Jedidiah Siev , David B. Yaden

{"title":"Psychedelics, OCD and related disorders: A systematic review","authors":"Marianna Graziosi , Julia S. Rohde , Praachi Tiwari , Jedidiah Siev , David B. Yaden","doi":"10.1016/j.jocrd.2024.100873","DOIUrl":null,"url":null,"abstract":"<div><p>This systematic review analyzes the current literature on the potential therapeutic use of classic psychedelics (i.e., psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine [DMT], 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT], mescaline, and other classic psychedelic analogs utilized in preclinical models) in obsessive-compulsive disorder (OCD) and related disorders. Our search identified 23 articles meeting our predetermined eligibility criteria, comprising 2 non-systematic reviews, 11 preclinical studies investigating the use of classic psychedelics or analogs in preclinical models of OCD, 8 case studies or case reports, and 2 clinical trials. This review provides an up-to-date synthesis of psychedelic OCD research, bridging preclinical findings, historical case reports, and initial clinical trial outcomes. Psilocybin appears to be the most widely used classic psychedelic and is well-tolerated in both OCD and body dysmorphic disorder (BDD) populations, with some participants experiencing significant symptom reduction. This review contributes to our understanding of the potential of classic psychedelics (in particular LSD and psilocybin) as novel therapeutic interventions for OCD and related disorders, offering insights into future research directions and clinical applications in this emerging field.</p></div>","PeriodicalId":48902,"journal":{"name":"Journal of Obsessive-Compulsive and Related Disorders","volume":"41 ","pages":"Article 100873"},"PeriodicalIF":1.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obsessive-Compulsive and Related Disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211364924000174","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

This systematic review analyzes the current literature on the potential therapeutic use of classic psychedelics (i.e., psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine [DMT], 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT], mescaline, and other classic psychedelic analogs utilized in preclinical models) in obsessive-compulsive disorder (OCD) and related disorders. Our search identified 23 articles meeting our predetermined eligibility criteria, comprising 2 non-systematic reviews, 11 preclinical studies investigating the use of classic psychedelics or analogs in preclinical models of OCD, 8 case studies or case reports, and 2 clinical trials. This review provides an up-to-date synthesis of psychedelic OCD research, bridging preclinical findings, historical case reports, and initial clinical trial outcomes. Psilocybin appears to be the most widely used classic psychedelic and is well-tolerated in both OCD and body dysmorphic disorder (BDD) populations, with some participants experiencing significant symptom reduction. This review contributes to our understanding of the potential of classic psychedelics (in particular LSD and psilocybin) as novel therapeutic interventions for OCD and related disorders, offering insights into future research directions and clinical applications in this emerging field.

查看原文本刊更多论文

迷幻剂、强迫症和相关障碍：系统回顾

这篇系统性综述分析了经典迷幻药（即麦角酰二乙胺[LSD]、麦角酰二乙胺[Psilocybin]、N,N-二甲基色胺[DMT]、5-甲氧基-N,N-二甲基色胺[5-MeO-DMT]、麦司卡林和其他在临床前模型中使用的经典迷幻药类似物）在强迫症（OCD）和相关疾病中的潜在治疗用途的现有文献。我们的搜索发现了 23 篇符合我们预先确定的资格标准的文章，其中包括 2 篇非系统综述、11 篇调查在强迫症临床前模型中使用经典迷幻药或类似物的临床前研究、8 篇病例研究或病例报告以及 2 篇临床试验。本综述对迷幻药强迫症研究进行了最新综述，将临床前研究结果、历史病例报告和初步临床试验结果联系起来。迷幻药似乎是使用最广泛的经典迷幻药，在强迫症和躯体畸形障碍（BDD）人群中的耐受性良好，一些参与者的症状明显减轻。这篇综述有助于我们了解经典迷幻药（尤其是迷幻剂和迷幻药）作为强迫症和相关障碍的新型治疗干预措施的潜力，为这一新兴领域的未来研究方向和临床应用提供了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Obsessive-Compulsive and Related Disorders PSYCHIATRY-

CiteScore

4.00

自引率

5.60%

发文量

审稿时长

47 days

期刊介绍： Journal of Obsessive-Compulsive and Related Disorders (JOCRD) is an international journal that publishes high quality research and clinically-oriented articles dealing with all aspects of obsessive-compulsive disorder (OCD) and related conditions (OC spectrum disorders; e.g., trichotillomania, hoarding, body dysmorphic disorder). The journal invites studies of clinical and non-clinical (i.e., student) samples of all age groups from the fields of psychiatry, psychology, neuroscience, and other medical and health sciences. The journal''s broad focus encompasses classification, assessment, psychological and psychiatric treatment, prevention, psychopathology, neurobiology and genetics. Clinical reports (descriptions of innovative treatment methods) and book reviews on all aspects of OCD-related disorders will be considered, as will theoretical and review articles that make valuable contributions. Suitable topics for manuscripts include: -The boundaries of OCD and relationships with OC spectrum disorders -Validation of assessments of obsessive-compulsive and related phenomena -OCD symptoms in diverse social and cultural contexts -Studies of neurobiological and genetic factors in OCD and related conditions -Experimental and descriptive psychopathology and epidemiological studies -Studies on relationships among cognitive and behavioral variables in OCD and related disorders -Interpersonal aspects of OCD and related disorders -Evaluation of psychological and psychiatric treatment and prevention programs, and predictors of outcome.